Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.690
-0.270 (-9.12%)
Dec 3, 2024, 12:44 PM EST - Market open
Fate Therapeutics Employees
Fate Therapeutics had 181 employees as of December 31, 2023. The number of employees decreased by 370 or -67.15% compared to the previous year.
Employees
181
Change (1Y)
-370
Growth (1Y)
-67.15%
Revenue / Employee
$74,293
Profits / Employee
-$984,702
Market Cap
306.38M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Cross Country Healthcare | 13,131 |
Cerus | 637 |
CVRx, Inc. | 200 |
Codexis | 174 |
Absci | 155 |
4D Molecular Therapeutics | 147 |
MaxCyte | 143 |
Kodiak Sciences | 111 |
FATE News
- 3 days ago - Fate Therapeutics Announces Leadership Transition - GlobeNewsWire
- 6 days ago - Fate Therapeutics to Present at Upcoming December Investor Conferences - GlobeNewsWire
- 12 days ago - Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha
- 15 days ago - Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - GlobeNewsWire
- 20 days ago - Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 23 days ago - Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - GlobeNewsWire
- 24 days ago - Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting - GlobeNewsWire
- 4 weeks ago - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire